Immunovia AB

Yesterday we were happy to announce that Immunovia has completed the analytical validation of our next-generation pancreatic cancer test. The validation demonstrated excellent results across a comprehensive set of parameters, reinforcing the reliability and robustness of the test. “We are happy to announce that our analytical validation results confirm the strong performance of our next-generation test.  This achievement validates the quality of our analytical method and marks an important milestone to provide a reliable, convenient test that could ultimately improve patient outcomes by enabling early detection of pancreatic cancer. We are excited to be moving to the next phase, clinical validation,” says Lisa Ford, PhD, HCLD(ABB), Lab Director at Immunovia.  Following the successful completion of the analytical validation, Immunovia has initiated a large-scale clinical validation study to assess the accuracy of our next-generation test. Read more about the news on the link below. #pancreaticcancer #earlydetection

Immunovia's Norma Alonzo Palma PhD presented data from model development study at 2024 AACR Pancreatic Cancer Conference, hosted by the American Association for Cancer Research.   During the conference, Immunovia shared results from the model development study of its next-generation test to detect stage 1 and 2 pancreatic cancer. “We are grateful to have been selected by the AACR reviewers to present the model-development-study results at this inspiring conference of pancreatic cancer advances. Rigorous scientific review and dissemination of our data will be critical for driving adoption of our next-generation test following its launch next year,” said Norma Palma PhD, Vice President of Clinical and Medical Affairs at Immunovia.    Read more about the presentation at the conference on the link below. #PancreaticCancer #EarlyDetection #AACR

Immunovia's CEO Jeff Borcherding presented at Aktiespararna Life Science Theme Night on August 28. See the entire presentation on the link below. #earlydetection #pancreaticcancer

Immunovia publishes Q2 Interim Report January-June 2024. Today at 15:00 CET, Immunovia will hold a webcast tele conference where Jeff Borcherding, CEO and President, and Karin Almqvist Liwendahl, CFO, will present on Immunovia’s development. The presentation will be held in English and be followed by a Q&A session. Link to webcast teleconference: https://lnkd.in/dY-KuR8C Read the press release and report on the link below. #pancreaticcancer #earlydetecion

Immunovia's CEO Jeff Borcherding presented at Redeye AB Investor Forum on May 16. See the entire presentation on the link below. #earlydetection #pancreaticcancer

Immunovia publishes Q1 Interim Report January-March 2024. Read the press release and report on the link below. Today at 15:00 CET, Immunovia will hold a webcast tele conference where Jeff Borcherding, CEO and President, and Karin Almqvist Liwendahl, CFO, will present on Immunovia’s development. The presentation will be held in English and be followed by a Q&A session. Link to webcast teleconference: https://lnkd.in/g5VEKyUP #earlydetection #pancreaticcancer

This week we announced the positive results from our model-development study for our next-generation test. In the study, Immunovia’s next-generation test demonstrated specificity of 98 percent and sensitivity of 75 percent in detecting early stage (1 and 2) pancreatic ductal adenocarcinoma (PDAC), a very aggressive and the most common form of pancreatic cancer. The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.    “Pancreatic cancer is a brutal and lethal cancer. People at risk for pancreatic cancer need a simple, fast, and easy blood test to detect cancer early. We are very excited about the potential of our test to meet this need and increase survival rates for these patients”, says Jeff Borcherding, CEO and President of Immunovia. Immunovia will now move to a second phase of the model development study, expected to be completed in 6 – 8 weeks, in which it will conduct additional statistical analyses to refine and assess the robustness of the test model.   Read more about the news on the link below.   #earlydetection #pancreaticcancer

Immunovia attended the Swiss Nordic Bio Conference last week in Zürich. At the event, our CEO Jeff Borcherding was interviewed by BioStock - Connecting Innovation and Capital, the leading Nordic life science media.   See the interview on the link below. #pancreaticcancer #earlydetection

Immunovia publishes Full Year Report for 2023. For complete press release: https://lnkd.in/dtmuNyzZ #pancreaticcancer #earlydetection

This week our CEO Jeff Borcherding is attending the J.P. Morgan Healthcare Conference to connect with prospective partners and investors about our mission to increase survival rates for patients with pancreatic cancer through early detection with our next-generation test. #PancreaticCancer #EarlyDetection